Patents Examined by George W Kosturko
  • Methods of treating cancer with small molecule NF-?B inhibitors
    Patent number: 11083729
    Abstract: The present invention provides, inter alia, compounds capable of inhibiting NF-?B. Pharmaceutical compositions containing and methods of using the compounds are also provided herein. Also provided are methods and kits for treating cancer and solid tumors in a subject, as well as methods and kits for inducing cancer cell death and apoptosis of a cancer cell, all utilizing the NF-?B inhibitors described herein.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: August 10, 2021
    Assignee: ImmuneTarget, Inc.
    Inventors: Samedy Ouk, Hsiou-Chi Liou
  • Combination drug
    Patent number: 11077093
    Abstract: The present invention relates to a drug that is for treating or preventing cancer, that is effective in the treatment of cancer, and that comprises a combination of an ALK inhibitor and a VEGF inhibitor. The present invention also relates to a method for treating or preventing cancer and a method for inhibiting tumor growth.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: August 3, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroshi Sakamoto, Toshiyuki Tsukaguchi
  • Methods of use of tetrahydroberberine (THB)
    Patent number: 11065244
    Abstract: Tetrahydroberberine (THB), isolated from the Chinese herb “Corydalis ambigua”, exhibits a variety of pharmacological effects, although mechanisms of action are unclear or entirely unknown. Described herein are novel methods of using tetrahydroberberine (THB), THB analogs or derivatives, tetrahydroprotoberberines (THPB). Tetrahydroberberine (THB) and analogs such as l-stepholidine (l-SPD) potently block functional KATP channels natively expressed on midbrain dopamine neurons. Further, THB also blocks pancreatic ?-cell KATP channels, and can be developed to a novel drugs for treating disease and/or conditions such as diabetes and Parkinson's disease.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: July 20, 2021
    Assignee: Dignity Health
    Inventor: Jie Wu
  • Combinations of opioid/TLR4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
    Patent number: 11058680
    Abstract: Disclosed are compositions for the treatment of emotional pain, physical pain, and insomnia comprising a compound comprising an opioid antagonist that treats pain by blocking Toll-like receptor 4 (TLR4). Examples of opioid antagonist include naltrexone and naloxone, and their use in the treatment, prevention, and reversal of pain.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: July 13, 2021
    Assignee: Allodynie Therapeutics, LLC
    Inventor: Annette Channa Toledano
  • Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor
    Patent number: 11053207
    Abstract: Disclosed are a compound represented by general formula I and a preparation method therefor. The compound can be used as indoleamine-2,3-dioxygenase inhibitor to prepare medicines for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: July 6, 2021
    Assignee: Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
    Inventors: Zhaoyin Wang, Wei Guo, Jidong Zhu
  • Applications for sulindac in preparing anti-lung cancer products
    Patent number: 11045436
    Abstract: This invention discloses uses for sulindac in preparing anti-lung cancer products. This invention provides uses for sulindac in the preparation of products to treat lung cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug sulindac, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that sulindac has a new use as an anti-lung cancer medication, thus achieving a new purpose for an old drug.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: June 29, 2021
    Assignee: SHANGHAI JIAO TONG UNIVERSITY
    Inventors: Yongyong Shi, Zhijian Song
  • Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
    Patent number: 11045432
    Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: June 29, 2021
    Assignee: Harrow IP, LLC
    Inventors: John Scott Karolchyk, Mark L. Baum
  • Agent for preventing and/or treating Alzheimer's disease
    Patent number: 11026942
    Abstract: The present invention provides a prophylactic or therapeutic agent for Alzheimer's disease (AD) containing a combination of two or more compounds selected from the group consisting of compounds shown by compound Nos. 1 to 130. Since these compounds are existing drugs that have already been confirmed actually for safety and pharmacokinetics in human, they can be a means for a pre-emptive treatment of people at risk of AD and in a stage before developing mild cognitive impairment (MCI).
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: June 8, 2021
    Assignee: KYOTO UNIVERSITY
    Inventors: Haruhisa Inoue, Takayuki Kondo
  • NRF2 activators
    Patent number: 11028099
    Abstract: The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: June 8, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Carl A. Brooks, Jay M. Matthews
  • Pharmaceutical quality strontium L-lactate
    Patent number: 11026906
    Abstract: The present application relates to strontium L-lactate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable strontium to mammals and treating or preventing symptoms of bone and/or cartilage disorders.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: June 8, 2021
    Inventor: Deanna J. Nelson
  • Pharmaceutical composition and methods of uses
    Patent number: 11013810
    Abstract: The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: May 25, 2021
    Assignee: Foresee Pharmaceuticals Co., Ltd.
    Inventors: Yuhua Li, ChiaTing Huang, John Mao
  • Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
    Patent number: 10993921
    Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: May 4, 2021
    Inventors: John Scott Karolchyk, Mark L. Baum
  • Application of clofoctol for manufacturing pharmaceutical product for treating human neuroglioma
    Patent number: 10987318
    Abstract: The present invention discloses an application of clofoctol for manufacturing a pharmaceutical product for treating human neuroglioma. The clofoctol is a pharmaceutical product for treating an upper respiratory tract infection. The clofoctol exerts a significant and specific inhibition of a glioma stem cell activity relative to a human neuroglioma cell or a normal human astroglia, human embryonic kidney cell, and human neural stem cell. A glioma stem cell treated with the clofoctol exhibited significantly reduced self-renewal, tumorsphere formation, and in vivo tumor formation in a nude rat. In vivo experiments using a zebrafish glioma transplantation model and a nude rat glioma transplantation model provided in vivo verification for the therapeutic efficacy of the pharmaceutical product against glioma.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: April 27, 2021
    Assignee: Institute of Medical Sciences, Chinese Academy of Medical Sciences
    Inventors: Xiaozhong Peng, Yan Hu, Wei Han, Boqin Qiang
  • Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies
    Patent number: 10980808
    Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: April 20, 2021
    Assignees: The Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Jun Qi, Dennis Buckley, Leonard I. Zon, Elizabeth Macari
  • Reversal of fosfomycin resistance
    Patent number: 10980811
    Abstract: Compounds, pharmaceutical compositions, and methods for reversing fosfomycin resistance are disclosed. Embodiments of the disclosed compounds inhibit fosfomycin-inhibiting enzymes. Some embodiments of the compounds are FosA inhibitors. The disclosed pharmaceutical compositions include (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) a compound, or a pharmaceutically acceptable salt thereof, which inhibits a fosfomycin-inhibiting enzyme. A method of inhibiting growth of a fosfomycin-resistant bacterium includes contacting the bacterium with (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: April 20, 2021
    Assignees: University of Pittsburgh—of the Commonwealth System of Higher Education, University of Maryland, Baltimore
    Inventors: Nicolas Paul Sluis-Cremer, Adam Daniel Tomich, Yohei Doi, Eric J. Sundberg, Erik H. Klontz, Steven Fletcher
  • Piperidine derivatives as HDAC1/2 inhibitors
    Patent number: 10968180
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: April 6, 2021
    Assignee: Regenacy Pharmaceuticals, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Melanin decomposition inhibitor
    Patent number: 10966911
    Abstract: To provide an inhibitor of melanin decomposition, which inhibits decomposition of melanin in keratinocytes to accelerate accumulation of melanin in skin and hair. An inhibitor of melanin decomposition in keratinocytes, comprising at least one selected from the group consisting of a plant extract containing berberine or a salt thereof, berberine or a salt thereof, proguanil or a salt thereof and phenformin or a salt thereof, as an active ingredient.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: April 6, 2021
    Assignee: Kao Corporation
    Inventors: Daiki Murase, Akira Hachiya, Naoki Oya, Kei Takano, Akiko Kawasaki, Keigo Kawabata
  • Pharmaceutical composition comprising solid dispersion of BCS class II drugs with Gelucires
    Patent number: 10952966
    Abstract: A solid pharmaceutical composition comprising a solid dispersion of a BCS Class II drug in a solid carrier/hydrophilic carrier; and a pH modifier. The solid carrier/hydrophilic carrier has a melting point of between about 40° C. to about 60° C. and an HLB value of between about 10 and about 18. The BCS Class II drug may be telmisartan.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 23, 2021
    Assignee: Gattefosse India Pvt. Ltd.
    Inventors: Nabil Farah, Sunil Bambarkar, Vincent Jannin, Chhanda Kapadia, Mangal Nagarsenker, Meenakshi Venkataraman, Megha Marwah
  • Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and new salts
    Patent number: 10933064
    Abstract: This application relates to various crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and salt thereof, as well as compositions and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various diseases, including carcinomas, specifically lung cancer and more specifically non-small cell lung cancer.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 2, 2021
    Assignees: Novartis AG, Palobiofarma S.L.
    Inventors: Kai Cui, Julio Cesar Castro-Palomino Laria, Weiyong Kong
  • ADO-resistant cysteamine analogs and uses thereof
    Patent number: 10906904
    Abstract: The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: February 2, 2021
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy